Brief: Newbury Pharmaceuticals Q2 EBITDA Loss Deepens To SEK 4.1 Million

Newbury Pharmaceuticals AB

15/04/2026 07:36

April 15 (Reuters) - Newbury Pharmaceuticals AB NEWBRY.ST:

Q2 NET REVENUE WAS 8 454 (12 434) TKR

Q2 EBITDA WAS -4 144 (-973) TKR

2026 OUTLOOK: SECOND HALF OF FINANCIAL YEAR IS EXPECTED TO SHOW STRONGER REVENUE THAN FIRST

2026 OUTLOOK: EXPECT IMPROVING GROSS MARGINS TO INCREASINGLY OFFSET FIXED COST BASE

Source text: ID:nMFN76c6dV

Further company coverage: NEWBRY.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))